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Biological rationale for the use of DNA
methyltransferase inhibitors as new strategy for
modulation of tumor response to chemotherapy
and radiation
Giovanni L Gravina1,2*, Claudio Festuccia2, Francesco Marampon1,2,3, Vladimir M Popov3, Richard G Pestell3,
Bianca M Zani2, Vincenzo Tombolini1,2

Abstract
Epigenetic modifications play a key role in the patho-physiology of many tumors and the current use of agents
targeting epigenetic changes has become a topic of intense interest in cancer research. DNA methyltransferase
(DNMT) inhibitors represent a promising class of epigenetic modulators. Research performed yielded promising
anti-tumorigenic activity for these agents in vitro and in vivo against a variety of hematologic and solid tumors.
These epigenetic modulators cause cell cycle and growth arrest, differentiation and apoptosis. Rationale for combining these agents with cytotoxic therapy or radiation is straightforward since the use of DNMT inhibitor offers
greatly improved access for cytotoxic agents or radiation for targeting DNA-protein complex. The positive results
obtained with these combined approaches in preclinical cancer models demonstrate the potential impact DNMT
inhibitors may have in treatments of different cancer types. Therefore, as the emerging interest in use of DNMT
inhibitors as a potential chemo- or radiation sensitizers is constantly increasing, further clinical investigations are
inevitable in order to finalize and confirm the consistency of current observations.
The present article will provide a brief review of the biological significance and rationale for the clinical potential of
DNMT inhibitors in combination with other chemotherapeutics or ionizing radiation. The molecular basis and
mechanisms of action for these combined treatments will be discussed herein.
A significant number of tumors are classified as poorly
or non-responsive to therapeutic drugs or radiotherapy.
Increasing the chemotherapeutic dosage or radiation
dose not only fails in improving the therapeutic
response, but it also contributes to the development of
side effects and resistance to therapy. An ideal strategy
would consist of the identification of anticancer agents
able to act synergistically with standard treatments such
as radiotherapy and chemotherapy, which would result
in triggering the cell death preferentially in tumor cells.
Many patients with neoplastic diseases exhibit hypermethylation of cytosine residues in gene promoters
which induce silencing of key tumor suppressor genes.
* Correspondence: giovanniluca.gravina@poste.it
1
Department of Experimental Medicine, Division of Radiation Oncology,
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Since methylation of CpG islands occurs infrequently in
normal cells, the modulation of this post-translational
modification may provide a selective tumor-specific
therapeutic target.
The packaging of DNA is critical for many DNA
metabolic processes including transcription, replication
and DNA repair. DNA is normally tightly wrapped
around histone octamers to form nucleosomes. These
primary elements have been traditionally thought as
stable DNA packaging units. However, it is now evident
that they are dynamic structures that can be altered by
different molecular processes [1-3]. These include (i)
incorporation of histone variants, which are thought to
have specialized functions [4], (ii) replacement, repositioning or, in certain cases, the removal of nucleosomes
by chromatin remodeling complexes, and finally (iii)
post-translational modifications.

© 2010 Gravina et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
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Post-translational modifications include (i) lysine acetylation and deacetylation, (ii) methylation, (iii) serine
phosphorylation and ubiquination and (iv) lysine sumoylation. These modifications play a major role in modeling higher-order chromatin conformation and modifying
the DNA accessibility to transcription factors [5,6].
Therefore, such changes are not strictly “genetic,” even
though the specific chromatin patterns are usually
inherited by daughter cells during replication.
In cancer, epigenetic silencing through methylation
occurs just as frequently as mutations or deletions and
leads to aberrant silencing of genes with tumor-suppressor functions [2,3].
Among the post-translational processes, DNA methylation is one of the most extensively characterized epigenetic modifications and its biological role is to maintain
DNA transcriptionally quiescent, resulting in gene silencing (Figure 1) [7-9]. This process is dependent upon
the action of DNA methyltransferases (DNMTs),
enzymes that catalyze the addition of methyl groups to
the 5’ carbon of the cytosine residues (Figure 1) [7]. Several isoforms of DNMTs are present in normal cells as
well as in tumor cells [9-11]. Existing evidence indicates
that DNMT1 appears to be responsible for maintenance
of established patterns of methylated DNA, while
DNMT-3a and -3b seem to mediate de novo DNA
methylation patterns [9-11]. Interestingly DNMT1 alone
is not sufficient for maintenance of abnormal gene
hypermethylation but the cooperation with DNMT3b
must occur for this function [12-14]. In the last years
many different DNMT inhibitors have been developed
(Table 1) and multiple molecular mechanisms by which
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DNMT inhibitors induce anti-cancer effects have been
identified. These mechanisms are partially mediated by
the hypomethylation of DNA with cytotoxic effects
documented at higher concentrations [8,15]. The net
effect is the modulation of specific genes involved in cellular processes such as apoptosis, cytostasis, differentiation and tumor angiogenesis [8,15]. Therefore, it is not
surprising that DNMT inhibitors are emerging as promising class of drugs in cancer treatment, especially in
combination with other agents or with other treatments
like radiotherapy. Even though some DNMT inhibitors
have entered into clinical trials, we currently have limited understanding of their precise mechanisms of
action, especially when combined with other available
treatments.
The present article will provide a brief review of the
biological significance and scientific rationale for the
clinical potential of DNMT inhibitors in combination
with chemotherapy or radiotherapy.

Combined therapy: Published Experience,
Ongoing Studies and Future directions
The goal of combining different treatments in the management of cancer is to increase and prolong the
response rate as well as to decrease the toxicity associated with each treatment. Two different strategies can
be utilized to achieve these objectives. Treatments may
be combined based on the absence of overlapping or
synergistic toxicities leading to empiric combinations.
A more sound approach is based upon the combination
of treatments with known convergent molecular
mechanisms.
It is well known that epigenetic abnormalities in cancer affect a plethora of genes involved in key cellular
pathways including cell cycle control, apoptosis, immune
recognition, angiogenesis tumor invasion and metastasis.
Consistent with the functional diversification of epigenetic alterations, epigenetic drugs are characterized by
pleiotropic effects which affect key aspects of tumor
biology leading to an overall impairment of the neoplastic potential of tumor cells. These are the reasons that
constitute the rationale for the proposed usage of
DNMT inhibitors as anticancer agents, alone or in combination with other treatments.
DNMT inhibitors and chemotherapy

Figure 1 Epigenetic modulation of gene expression by posttranslational DNA methylation. Transcriptionally inactive
chromatin is characterized by the presence of methylated cytosines
within CpG dinucleotides (CH3), which is sustained by DNA
methyltransferases (DNMTs).

Despite the promising anticancer activity in haematological malignancies [16], early clinical trials showed that
DNMT inhibitors have low anticancer activity and significant toxicity as single agent in solid tumors. Recent
studies, however, suggest that low concentrations of
DNMT inhibitors such as 5-Aza and decitabine may act
synergistically when combined with chemotherapy
and contribute to overcoming intrinsic or acquired
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Table 1 Overview of some DNMT inhibitors with their mechanisms of action
Name

Chemical nature

Mechanism of action

Azacitidine

Ribonucleoside
analogue

This drug is a ribonucleoside analogue and it binds to RNA and DNA. This molecule interrupts mRNA
translation and when incorporated into DNA inhibits methylation by trapping DNMTs. At relatively
higher concentrations this drug results in the formation of high levels of enzyme-DNA adducts.

Decitabine

Deoxyribonucleoside
analogue

This drug is a deoxyribonucleoside analogue. For this reason, this molecule does not bind to RNA but
only to DNA. When incorporated into DNA inhibits methylation by trapping DNMTs resulting in the
reduced methylation of cytosines in DNA synthesized after drug treatment. When used at relatively
high concentrations this drug results in the formation of high levels of enzyme-DNA adducts,

Zebularine

Deoxyribonucleoside
analogue

This drug is a deoxyribonucleoside analogue. For this reason, this molecule does not bind to RNA but
only to DNA. When incorporated into DNA inhibits methylation by trapping DNMTs resulting in the
reduced methylation of cytosines in DNA synthesized after drug treatment. When used at relatively
high concentrations this drug results in the formation of high levels of enzyme-DNA adducts,

(−)-epigallocatechin- Non-nucleoside
3-gallate
analogue
MG98

Non-nucleoside
analogue

This antisense oligonucleotide targets the 3 UTR of DNMT1 causing a methylation decrease in cell
lines and animal models

RG108

Non-nucleoside
analogue

This small molecule is not incorporated into DNA but i bind to the catalytic site of DNMTs causing
inhibition of DNA methylation

Procainamide

Non-nucleoside
analogue

This molecule reduces DNMT1’s affinity
for both DNA and S-adenosyl-methionine causing a decrease in DNA methylation

chemoresistance [17-19]. These properties are considered clinically significant as the resistance of tumor cells
to cytotoxic agents remains the major obstacle in chemotherapeutic-based treatments. The mechanisms
underlying chemoresistance remain in some measure
elusive even though multifactorial mechanisms, including epigenetic modifications may drive this mechanism
[20-25]. Therefore, any effort to overcome multi-drug
resistance represents the primary goal in cancer
research. Based on the chemical mechanisms, DNMT
inhibitors act through different mechanisms. Among the
different mechanisms postulated, alterations in differentiation, changes in apoptosis, and induction of a beneficial immune response are considered of main
importance [19]. Finally, the induction of DNA damage
due to the formation of irreversible covalent enzymeDNA adducts has also been taken into consideration.

1 and Akt (Figure 2). The functional loss of PTEN is
higher than that attributable to LOH of chromosome
10q and post-translational mechanisms, including hypermethylation, explain the other part of this phenomenon
[31-34]. Evidence indicates that 5-Aza is a chemosensitizer in prostate cancer [35] and its property seems
mediated by PTEN. After infection with a recombinant
adenovirus containing wild-type PTEN, bladder tumor
cells acquire greater chemosensitivity to the cytotoxic
effect of doxorubicin [36-39]. The chemosensitivity
induced by PTEN is partially mediated by PI3K
and Akt/PKB [40]. Other evidence, in a different

Cell signaling

Cell signaling is a complex system of communication
that coordinates basic cellular activities. Cells perceive
and correctly respond to microenvironment via this
complex system engaging in cellular processes such as,
tissue repair, immunity, as well as normal tissue homeostasis. Errors in cell signaling are involved in the development as well as in the progression of cancer and
aberrant DNMT activity has been involved in these processes. PTEN (phosphatase and tensin homolog deleted
on chromosome ten) is a tumor suppressor gene and its
functional loss has been documented in bladder cancer,
glioblastoma, melanoma and cancers of the prostate,
breast, lung and thyroid [26-30]. This tumor suppressor
gene controls PI3K by preventing the activation of PDK-

Figure 2 DNMT inhibitors and PTEN/PI3K/Akt pathway. PTEN/
PI3K/Akt pathway physiologically plays a key role in the control of
many processes essential for the cellular life. The tumor suppressor
PTEN negatively controls the PI3K/Akt pathway and its epigenetic
loss, frequent in cancer cells, leads to the aberrant pathway
activation. DNMT inhibitors restore the PTEN expression by
epigenetic mechanisms.
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experimental model, suggests that the transfection of
TC-32 Ewing sarcoma cells with Akt/PKB inhibits doxorubicin-induced apoptosis suggesting that PTEN
increases doxorubicin cytotoxicity through the PI3K signaling pathway. Additional indication of chemosensitizing properties of PTEN derived from data obtained in
endometrial cancer cells [41]. In this system, PTEN significantly enhanced chemosensitivity to doxorubicin.
This effect was associated with the levels of phosphoAkt/PKB and phospho-Bad (Ser-136), which were
reduced in the PTEN expressing clones. Results from
other studies performed on brain tumors clearly show
that decreasing activity of the PI3K/Akt pathway in
tumor cells with mutant PTEN may contribute to the
increased sensitivity to chemotherapy [42]. Down-regulating the Akt pathway by inducing PTEN also increases
the sensitivity of glioblastoma cells to temozolomide.
DNA base damage

Some kind of acquired or intrinsic chemoresistance may
be epigenetic in nature and operate at DNA mismatch
repair level [43-48]. Interestingly, suppression of a DNA
mismatch repair mechanism seems [49] to act in concert
with other independent DNA mismatch repair machineries [50,51], resulting in drug resistance and genetic
instability [52]. The suppression of DNA mismatch repair
mechanism can occur at epigenetic level and in the
absence of heritable inactivating mutations. Demethylating
agents have been shown to reverse drug resistance to alkylating agents in some preclinical models of ovarian and
colorectal cancer [53]. This process may happen through
up-regulation of MLH1, and is mediated by 5-Aza treatment, which sensitizes tumor cells to cisplatin. However,
5-Aza treatment does not sensitize MLH1 mutant cells to
cisplatin, indicating that MLH1 gene reactivation is
required for the sensitization [53,54]. If MLH1 reactivation
is required for the sensitization to cisplatin, several concerns still exist about the value of epigenetic modulation
of DNA repair genes in inducing chemosensitization. It is
well known that MGMT, another DNA repair mediator, is
frequently epigenetically silenced [55]. Consistent with its
role in protecting the genome from G to A transitions,
induced by alkylating agents, MGMT inactivation through
its promoter hypermethylation has been associated with G
to A mutations in k-ras and p53 genes in colorectal cancer
[56,57]. Even though DNMT inhibitors, such as 5-Aza and
decitabine, have proven effective in re-expressing MGMT
in cancer cells, the clinical advantage of the restored
MGMT expression is doubtful [58-60] since tumors with
the unmethylated promoter of MGMT gene appear significantly less susceptible to the cytotoxic effects of alkylating
drugs [56,57,60].
Although the biological effects of DNMT inhibitors on
methylation and demethylation status of DNA mismatch
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repair genes have been extensively studied, DNA
damage-related sequelae of these agents is still not fully
understood. DNA Double Strand Breaks (DSBs) are the
most cytotoxic DNA lesions. One-ended DSBs can be
formed via collapse of a replication fork at the site of a
blocking DNA lesion [61-64]. Given that DNMT inhibitors, as well as some chemotherapeutics, create irreversible covalent DNA-enzyme adducts, the convergence of
these phenomena may be one possible mechanism by
which these two agents synergize and induce cytotoxicity
[65,66]. Several reports indicate that 5-Aza, decitabine
and zebularine induce DSB responses followed by
induced apoptosis. These responses may be mediated via
ATR or ATM, which are two key mediators promoting
DNA DSB response signalling [67-69]. Given that the
DSB responses induced by 5-Aza and doxorubicin engage
in distinct signaling pathways, the combination of these
two agents may cooperate and synergistically induce cell
death [70]. The induction of DNA damage response by
Chk2 and p53 phosphorylation could be another
mechanism by which DNMT inhibitors induce DNA
damage-related sequelae and cooperate with chemotherapeutics [71-75]. In this regard, some studies revealed that
decitabine may be cytotoxic against both p53 wild-type
and p53 mutant containing tumor cells, suggesting that
p53 function is not always required in order to mediate
the apoptotic process of DNMT inhibitors. Finally, it has
been demonstrated that these agents can induce DNA
damage in a dose-dependent manner, while the degree
and the kind of DNA damage induced parallels the
amount of incorporated DNMT inhibitor [76]. This may
be an important cooperative mechanism since when the
cytotoxic effect of DNMT inhibitors takes place in close
proximity of a single- or double-strand break induced by
chemotherapeutics the damage may be lethal.
Apoptosis

Defects in apoptotic pathways promote chemoresistance.
DNMT inhibitors are known to potentiate apoptotic
processes through different pathways. Evidence suggests
that the induction of TRAIL by decitabine is critical for
sensitizing breast cancer cells to Adriamycin. The silencing of TRAIL decreases caspase activation and abrogates chemosensitization mediated by decitabine. Several
mechanisms by which DNMT inhibitors induce TRAIL
have been postulated. One of the possible mechanisms
is the activation of TRAIL gene expression [77,78].
Additional evidence suggests that the induction of
TRIAL by decitabine is mediated by the increase in the
half-life of TRAIL protein [78] or by the induction of
TRAIL via Akt. It is known that the PI3K inhibitor
wortmannin can induce TRAIL [79], and that the overexpression of the active form of Akt can abolish TRAIL
induction mediated by wortmannin. In agreement with
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this evidence, Akt, working as a negative modulator of
TRAIL, is modulated by 5-Aza resulting in a decrease of
phosphorylated Akt and enhanced TRAIL expression.
If TRAIL plays a key role in the apoptotic process
mediated by DNMT inhibitors, other investigators suggest that the methylation in the promoter region of caspase 8 and caspase 9 is another well known mechanism
by which tumors acquire chemoresistance. Mechanistic
studies indicate that decitabine induces caspase-8 and
caspase-9 and sensitizes tumor cells to TRAIL, etoposide, cisplatin [80,81] and paclitaxel [82].
Overexpression of the Activator protein 2a (AP-2a) is
another mechanism through which DNMT inhibitors
may induce apoptosis and influence chemosensitivity.
AP-2a is a sequence-specific DNA-binding transcription
factor that is required for regulation of many genes
involved in many biological functions [83-85]. Growth
inhibitory activity of AP-2a is mediated through direct
interaction with p53 [86] and the overexpression of this
transcription factor induces cell cycle arrest and apoptosis [87,88]. Epigenetic targeting of AP-2a inhibits tumor
proliferation and increases tumor cell death [89]. This
acquires a meaningful clinical significance considering
that 75% of invasive breast tumors have epigenetically
silenced AP-2a. Therefore, the use of DNMT inhibitors
may provide the unique opportunity for modifying the
chemosensitivity of breast cancer containing hypermethylated and silenced AP-2a [90-95].
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epigenome may play a critical role to oxidative stress
and highlights a potential role of DNMT1 activity abrogation as a potential molecular target in chemoresistant
tumor cells. This evidence has been further confirmed
showing that the selective silencing of DNMT1 and
DNMT3b greatly reduces the chemoresistance of tumor
cells overexpressing DNMTs isoenzymes [115].
DNMT inhibitors and radiotherapy

The therapeutic index of radiotherapy can be improved
by chemical agents that sensitize cancer cells to the
toxic effects of ionizing radiation. Radiotherapy and systemic agents may interact through two main modalities
(Figure 3). In the first modality, radiotherapy acts locoregionally and systemic agents act against micro-metastases without interaction between the treatments. In the
second modality radiotherapy and systemic agents interact within the radiation field increasing tumor cell
death.
Sparse biological data indicate that DNMT inhibitors
may act as radiosensitizers. The meaningful advantage
of DNMT inhibitors as radiosensitizers is that these
agents can induce radiosensitization at concentrations
several times lower than typical plasma levels obtained
when used as single agents [116]. Major interactions
between DNMT inhibitors and radiotherapy may be
postulated. For clearer understanding, the potential biological mechanisms of cooperation between DNMT
inhibitors and radiotherapy will be discussed separately.

Oxidative stress

DNA repair

Agents inducing oxidative stress determine cellular
damage by reactive oxygen intermediates (ROI). Small
amounts of ROI may act as signalling molecules but if
ROI production exceeds the endogenous intracellular
antioxidative capacities [96,97] an oxidative stress occurs
[98] resulting in cell death. Increased ROI levels contribute to the development of chemoresistance and growing evidence supports a role of epigenetic processes in
ROS-induced generation of oxidative stress [99-105].
The proto-oncogene AP-1 plays a central role in the
control of cellular response to oxidative stress [106-109].
It modulates the expression of target genes involved in
protective and/or reparative cellular responses to the
damaging effects of oxidative stress [110-113]. Experimental data suggest that H2O2 stress-resistant tumor
cells have increased AP-1 DNA-binding activity and are
resistant to the damaging effects of chemotherapeutic
agents [114]. The inhibition of the AP-1 complex
reverses the multimodality resistance phenotype
(MMRP) in response to oxidative stress through the
inhibition of Fos activity [114]. Other studies have
expanded these observations showing that DNMT1, a
downstream target of Fos, is upregulated in chemoresistant tumor cells [114]. These results indicate that the

Radiation therapy induces DNA base damage, singlestrand breaks, and double-strand breaks (DSBs). These
structural damages are repairable, except for DSBs,
which are considered lethal [116]. 5-Aza, decitabine and
zebularine lead to protein-DNA adducts and when the

Figure 3 Rationale for combining DNMT inhibitors and
radiation therapy. Spatial and in-field cooperation are the two
modalities of cooperation mechanisms between DNMT and ionizing
radiation.
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MTase levels [123], and (iii) decitabine induce p53 DNA
damage response by MTase-DNA adducts [124-127].
Cell cycle

Figure 4 Cooperative cytotoxic mechanism between DNMT
inhibitors and radiation. Ionizing radiation induces DNA base
damage, single-strand breaks, and double-strand breaks (DSBs). All
of these errors can be rapidly repaired except for DSBs, which if not
repaired are considered lethal. The cytotoxic effect of DNMT
inhibitors in close proximity to a radiation-induced single-strand
break can act synergistically to make the defect significantly more
difficult to repair, consequently resulting in the induction of cellular
death.

cytotoxic effect takes place in close proximity to a radiation-induced single-strand break, the damage may be
significantly more difficult to repair (Figure 4). The
DNA cytosine-C5 methyltransferase (MTase) acts on a
cytosine residue through its recognition sequence by
covalently binding to C6, and then transferring the
methyl group from S-adenosylmethionine to C5. The
covalent protein-DNA linkage is then reversed and the
enzyme dissociates from the DNA. In this context, 5Aza, decitabine and zebularine substitution at the target
cytosine interferes with the reaction cycle, which results
in long-lived or irreversible MTase-DNA adducts
[117-121]. The cytotoxic mechanism of DNMT inhibitors has been documented in in vivo models. Results
from these studies suggest that (i) the formation of protein-DNA adducts mediate decitabine cytotoxicity [122],
(ii) the cytotoxicity levels correlate positively with

Figure 5 Cell cycle, DNMT inhibitors and radiosensitivity. The
radiosensitivity of cells is dependent on the phase of the cell cycle.
Cells in the S phase are the most radio resistant, and cells in the
G2-M phase of the cell cycle are the most radiosensitive. DNMT
inhibitors synchronize with the cell cycle of tumor cells increasing
the efficacy of subsequent radiotherapy.

The radiosensitivity of tumor cells is dependent on the
phase of the cell cycle. Cells in the S-phase are the most
radioresistant, whereas cells in the G2-M phase are the
most radiosensitive. Evidence indicates that DNMT inhibitors synchronize tumor cells preferentially in the G1
or G2/M phase of the cell cycle increasing the efficacy
of radiotherapy (Figure 5). In this way, if administered
concurrently to radiotherapy, the inhibitors may cooperate to produce additive or synergistic antitumor
effects. Qui and co-workers demonstrated that low concentrations of decitabine synchronize gastric tumor cells
in the G2/M phase of the cell cycle and induce radiosensitization [116]. The radiosensitizing effect of this
inhibitor seems to be partly mediated by p53, RASSF1,
and DAPK [116]. RASSF1 and DAPK modulate multiple
apoptotic and cell-cycle checkpoint pathways [128,129]
and the loss of RASSF1 and DAPK expression is documented in a wide range of human tumors as a result of
silencing, primarily from promoter hypermethylation
[130]. Therefore, the epigenetic modulation of RASSF1
and DAPK shines some light on the synergism between
DNMT inhibitors and radiotherapy in terms of apoptotic signaling modulation.
Angiogenesis

Induction of anti-angiogenic activity in radiotherapy as a
result of combined treatments with DNMT inhibitors is
backed by a clear rationale. Common in many cancers
hypoxia has been indicated as a marker of aggressive
clinical behaviour, poor prognosis and unsatisfying
radiation response. Therefore, any compound able to
increase perfusion and oxygenation reduces the radioresistant hypoxic areas counteracting the onset of hypoxic
and radioresistant clones.
Experimental data suggest that many key modulators of
angiogenesis are under epigenetic control. The promoter
of von Hippel-Lindau (VHL) tumor suppressor gene is
hypermethylated and its absence leads to a failure in
degradation of hypoxia inducible factor (HIF)-1 whose
accumulation favors tumor angiogenesis [131]. This aberrant pathway has been successfully inactivated by decitabine, which in addition to restoring VHL expression,
down-regulates the vascular endothelial growth factor
(VEGF), the glucose transporter (GLUT)-1 [132] and the
thrombospondin-1 [133]. Radiotherapy has been shown
to kill proliferating endothelial cells. Therefore, any drug
that acts on endothelial cells induces a significant
increase in the cytotoxic effect of radiotherapy decreasing
the levels of angiogenesis. DNMT inhibitors act directly
on activated endothelial cells and inhibit angiogenesis in
vitro and in vivo [132]. Decitabine and its analogue zebularine exhibit significant angiostatic activity. This is
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accompanied by a significant effect on the expression
levels of angiogenesis inhibiting genes (TSP1, JUNB, and
IGFBP3). TSP1 is known to block endothelial cell migration and to induce apoptosis. JUNB negatively regulates
cell growth by activating p16INK4A and decreasing
cyclin D1 expression [132], while IGFBP3, a key regulator
of cell growth and apoptosis, inhibits VEGF-mediated
HUVEC proliferation [133] and angiogenesis [133]. Reexpression of these growth-inhibiting genes by DNMT
inhibitors, in activated endothelial cells, may contribute
to a decrease in angiogenesis and improvement in intrinsic radiosensitivity.
Apoptosis

Apoptosis is a well known mechanism through which
antitumor agents induce radiosensitization. DNMT inhibitors sensitize tumor cells to apoptosis either by restoring the defective expression of apoptotic effector
proteins, or by re-establishing the expression of signal
transducing/mediators of the apoptotic signals. 5-Aza
restores the expression of DAPK1 in bladder carcinoma
and B-cell lines [134] and the re-expression of DAPK1
in Burkitt’s lymphoma cell lines restores the susceptibility to IFN-a triggered apoptosis [135]. Similarly, DNMT
inhibitors sensitize NSCLC cells to TRAIL-induced
apoptosis by inducing DAPK1 expression [136]. Besides
DAPK1, 5-Aza and DNMT1 antisense oligonucleotides
are able to restore the sensitivity of cancer cells to IFNtriggered apoptosis despite the re-expression of the proapoptotic gene RASSF1A and XAF1 which are frequently silenced by epigenetic mechanisms [137,138].
Caspases are not spared from epigenetic inactivation
during tumor transformation. Hypermethylation of caspase-8 promoter leads to its either reduced expression
or complete absence in neoplastic cells resulting in their
resistance to death receptor and drug-induced apoptosis.
However, 5-Aza has proven to be effective in re-establishing caspase-8 expression in cancer cells, restoring
their sensitivity to TRAIL-, anti-FAS-, and drug-triggered apoptosis [35,139-141].
Cell signaling

DNMT inhibitors are modulators of gene expression
and may increase the expression levels of many key
genes, specifically the ones involved in the radiosensitizing processes. NF-B is capable of activating a number
of genes involved in stress response, inflammation, and
apoptosis. Loss or inhibition of NF-B activation leads
to radio-sensitization [142-144]. The elevated basal NFB activity in certain cancers has been linked with
tumor resistance to chemotherapy and radiation [145].
Together with the assumption that NF-B is capable of
regulating more than 150 effector genes, this transcription factor plays a key role in tumor radioadaptive resistance under fractional ionizing radiation. 5-Aza can
rapidly induce inhibition of NF-kB [146]. This effect
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may be achieved via down-regulation of pro-survival
and anti-apoptotic (IL-6, IL-6Ra, Bcl-XL) mediators or
abrogating drug-induced NF-kB stress responses
[147,148]. PARP-1 represents the essential transcriptional co-regulator implicated in radiation-induced NFB, AP-1, Oct1, and HIF-1a activation [149]. Experimental results demonstrate that the ATM gene is a target for silencing through aberrant methylation of its
proximal promoter region [150,151]. This epigenetic
event can result in a decreased expression of ATM,
resulting in a radioresistant phenotype consistent with
reduced ATM function. DNMT inhibitors, positively
affecting the levels of ATM, increase radiosensitivity in
human colorectal tumor cell lines. In this regard, the
moderate radiosensitivity displayed by HCT-116 cells
can be increased by 5-azacitidine treatment, correlating
with ATM levels [151].
Epigenetic control of oncogenes: implication for standard
treatments

Global genomic hypomethylation has been documented
in most solid tumors [152-154]. Evidence suggests that
this post-translational mechanism supports tumor development [155]. In solid human tumors, a correlation
between global genomic hypomethylation and advanced
tumor stage has been established [154].
Methylation has been primarily considered as a
mechanism for tumor suppressor genes silencing and
genome profiling approaches have identified several
putative tumor suppressor genes silenced by promoter
hypermethylation. So far, unmasked expression of putative oncogenes has been sporadically reported [156].
Although c-myc was among the very earliest oncogenes identified and the subject of intense study, it has
nonetheless proven to be an enduring enigma. Results
to date suggest that Myc-Max influences cell growth
and proliferation through direct activation of genes
involved in DNA synthesis, RNA metabolism and cellcycle progression [157]. Early studies showed that c-myc
is under epigenetic control and its functional silencing
sensitizes cancer cells to chemotherapy and radiotherapy
[158-160]. These sensitizing effects of c-Myc were primarily achieved by inhibiting MLH1 and MSH2 mismatch repair proteins [161]. Evidence suggests that
decitabine is unable to modify the expression of c-myc
in gastric cancer [161]. Other evidence, however, suggest
that several proto-oncogenes, whose promoters are
under epigenetic control, may be down-regulated rather
than up-regulated after treatment with epi-drugs [162].
Microarray data revealed that the treatment of myeloma
multiple cells by decitabine and TSA resulted in downregulation of several proto-oncogenes such as members
of myc family [162]. Of note, the down-regulation of
these genes was more a response to TSA and
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decitabine/TSA than to decitabine alone. The biological
rationale for this surprising phenomenon is not well
known although this effect may be explained either by a
direct inhibitory action of decitabine and TSA or by an
indirect down-regulation by decitabine and TSA affected
genes [162].
Therefore, these conflicting data may have important
therapeutic implications since demethylation-based therapy can cause unintended effects. It may be possible
that in certain tissues and under selective biological conditions epi-drugs may result in either up- or down-regulation of proto-oncogenes [163]. These concerns may
explain either some of the side effects or the unsuccessful results documented upon demethylation-based therapy in solid tumors.
Response of normal tissues to DNMT inhibitors

The use of DNMT inhibitors raises questions regarding
their potential to epigenetically affect non-cancerous
cells. Therefore, an important issue is a need for a
more complete understanding of the potential benefits
and limitation of DNA methylation as a human cancer
drug target. Conflicting evidence exist in literature
regarding the effect of DNMT inhibitors on normal
cells. Even though well known toxicity profile has been
documented for DNMT inhibitors, especially for
nucleoside analogues such as 5-Aza and decitabine in
the clinical setting (Table 2), many doubts exist about
their long-term safety as well as about their mutagenic
and carcinogenic potential [164]. Some evidence indicate that intraperitoneal injection of 5-Aza at doses
ranging from 2.0 to 2.2 mg/kg for 50-52 weeks in murine models increased the incidence of malignant
tumors of hematopoietic and lymphoreticular system
as well as of lung, mammary glands and skin [165].
The mutagenic potential of 5-Aza [165] and decitabine
[166] was tested in vitro and in vivo systems. Both analogues increased mutation frequency in L5178Y mouse
lymphoma cells, and mutations were produced in an
Escherichia coli lac-I transgene in colonic DNA of decitabine-treated mice [166]. Decitabine, moreover,
resulted in chromosomal rearrangements in larvae of
fruit flies. The effect of decitabine and 5-Aza on postnatal development and reproductive capacity was evaluated in murine models. Administration of these
inhibitors in male mice resulted in decreased fertility
and loss of offspring during subsequent embryonic and
postnatal development. Decreased weight of the testes
and epididymides with reduced sperm counts were
also detected. Body weights of males and females
exposed in utero to decitabine were significantly
reduced at all postnatal time points. No consistent
effect on fertility was seen when female mice exposed
in utero.
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However, if the aforementioned data indicate that
both 5-Aza and decitabine have a tangible toxicity on
normal tissues, recent biological data seem to suggest
that normal cells may interact differently with DNMT
inhibitors than malignant cells. In this regard, some data
suggest that normal cells, dividing at a slower rate than
malignant cells, incorporate less drug than cancer cells
into their DNA resulting in decreased effect on DNA
methylation. Zebularine, a novel DNA methyltransferase
inhibitor, has properties of acting differentially on cancerous and normal cells. Continuous treatment with this
drug substantially reduces the growth rate of human
cancer cells with less effect on normal human fibroblasts. Growth inhibition in cancer cells was found to be
associated with the induction of p21 which was unmodified in human fibroblasts. This suggests that the growthsuppressive potential of zebularine in tumor cells is seemingly p21-dependent and its differential effects was
partially due to preferential incorporation of zebularine
into DNA of tumor cells as documented by the uridine/
cytidine kinase activity levels that were generally higher
in cancerous than normal cells. Therefore, the preferential effects of zebularine in cancer cells in terms of
incorporation into DNA, growth inhibition, demethylation, and depletion of DNMTs are probably due to differential metabolism compared to normal cells.
If different metabolism between normal and malignant
cells may partially explain the preferential effect of
DNMT inhibitors on tumor cells [167], the differential
genes expression that these inhibitors induce in different
cellular sub-populations is equally relevant. Karpf and
coworker conducted a genomic analysis of gene expression modifications upon decitabine treatment both in
normal and cancerous cell lines. In their analysis the
authors concluded that decitabine (i) elicited changes in
a limited number of genes, (ii) regulated gene expression
similarly between normal and cancer cells, and (iii)
changes in the expression of specific genes required the
presence of transcriptional activators competent for activation of the target promoter [168,169]. However, if the
differences in gene expression patterns between normal
and malignant cells upon DNMT inhibitors seem to be
less marked than previously seen, the selective activation
of specific genes in tumor cells is clearly documented in
literature. In this regard, decitabine leads to the selective
activation of specific genes only in tumor cells opening
to the intriguing hypothesis that DNMT inhibitors may
increase the therapeutic index of specific antitumor strategies consenting of targeting the gene products differentially expressed in tumor cells [169].
Xerostomia is a common complication of radiotherapy
on head and neck cancer due to irreparable damage
caused to the salivary glands if they are included in the
radiation fields. This side effect is perceived negatively
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Table 2 Clinical toxicity
5-Azacitidine

Decitabine

General

Pyrexia, fatigue, weakness, rigors, pain in limb, back pain,
Pyrexia, peripheral edema, rigors, edema, pain, lethargy,
contusion, dizziness, erythema, chest pain, epistaxis, myalgia,
tenderness, fall, chest discomfort, intermittent pyrexia, malaise,
decreased weight, abdominal pain, aggravated fatigue,
crepitations.
abdominal tenderness, insomnia, malaise, pain, upper abdominal
pain, night sweats, lethargy, peripheral swelling, transfusion
reaction, abdominal distension, syncope, chest wall pain,
hypoesthesia, post procedural pain, general physical health
deterioration, systemic inflammatory response.

Local

Injection site erythema, injection site pain, injection site bruising, Erythema, catheter site pain, and injection site swelling.
injection site reaction, injection site pruritus, injection site
granuloma, injection site pigmentation changes, injection site
swelling.

Cardiovascular
Respiratory

Cardiac murmur, hypotension, pulmonary edema.
cough, dyspnea, nasopharyngitis, exertional dyspnea, productive
cough, pneumonia, lung crackles, rhinorrhea, rales, wheezing,
decreased breath sounds, pleural effusion, postnasal drip,
rhonchi, nasal congestion, atelectasis, exacerbated dyspnea,
sinusitis, hemoptysis, lung infiltration, pneumonitis, respiratory
distress

cough, pharyngitis, lung crackles, decreased breath sounds,
hypoxia, rales, postnasal drip.

Musculoskeletal arthralgia, muscle cramps, aggravated bone pain, muscle
weakness, and neck pain.

arthralgia, limb pain, back pain, chest wall pain, musculoskeletal
discomfort, myalgia

Hematologic

anemia, thrombocytopenia, leukopenia, neutropenia, febrile
neutropenia, hypokalemia, post procedural hemorrhage,
aggravated anemia, agranulocytosis, bone marrow depression,
bone marrow failure, pancytopenia, and splenomegaly.

neutropenia, thrombocytopenia, anemia, febrile neutropenia,
leukopenia, lymphadenopathy, and thrombocythemia.

Gastrointestinal nausea, vomiting, diarrhea, constipation, anorexia, pharyngitis,
appetite decreased, gengival bleeding, oral mucosal petechiae,
stomatitis, dyspepsia, hemorrhoids, loose stools, dysphagia,
mouth hemorrhage, tongue ulceration, diverticulitis,
gastrointestinal hemorrhage, melena, perirectal abscess

nausea, constipation, diarrhea, vomiting, abdominal pain, oral
mucosal petechiae, stomatitis, dyspepsia, ascites, gingival
bleeding, hemorrhoids, loose stools, tongue ulceration,
dysphagia, oral soft tissue disorder, lip ulceration, abdominal
distension, abdominal pain upper, gastroesophageal reflux
disease, glossodynia.

Dermatologic

ecchymosis, rash, erythema, skin lesion, pruritus, alopecia,
urticaria, and facial swelling.

ecchymosis, petechiae, skin lesions, rash, pruritus, increased
sweating, urticaria, dry skin, skin nodule, pyoderma
gangrenosum, pruritic rash, and skin induration.

Immunologic

Infections and infestations such as pneumonia, cellulitis, candidal
infection, catheter related infection, urinary tract infection,
staphylococcal infection, oral candidiasis, sinusitis, bacteremia.

Nervous
System

headache, convulsions, intracranial hemorrhage.

headache, dizziness, hypoesthesia, insomnia, confusional state,
anxiety.

Others

pallor, pitting edema, lymphadenopathy, hematoma, cellulitis,
infections and infestations including herpes simplex, limb
abscess, bacterial infection, blastomycosis, injection site infection,
Klebsiella sepsis, streptococcal pharyngitis, Klebsiella pneumonia,
sepsis, Staphylococcal bacteremia, Staphylococcal infection,
neutropenic sepsis, septic shock, toxoplasmosis, genitourinary
infection, hematuria.

vascular disorders such as petechiae, pallor, hematoma,
increased blood alkaline phosphatase, aspartate
aminotransferase, blood urea, blood lactate dehydrogenase,
blood bicarbonate, decreased blood albumin, blood chloride,
protein total, blood bicarbonate, blood bilirubin, hyperglycemia,
hypoalbuminemia, hypomagnesemia, hypokalemia,
hyponatremia, decreased appetite, anorexia, hyperkalemia,
dehydration, hyperbilirubinemia, transfusion reactions, blurred
vision, dysuria, urinary frequency.

by many patients with a significant impact on their
quality of life. This condition is partially due to the
death of a significant number of glandular ductal cells,
which if not replaced, result in a significant decrease in
the amount of produced saliva. Motegi and coworkers
examined the mechanism by which immortalized normal human salivary gland ductal cells acquire the ability
to express Aquaporin 5 (AQP5) and secrete fluid in
response to decitabine treatment [170]. AQP5 is a water
channel protein and its role in the generation of saliva,

tears and pulmonary secretion is well documented.
These authors suggest that decitabine resulted in AQP5
gene expression in human salivary gland ductal cells
(NS-SV-DC cells) affecting the water permeability by
increasing the transepithelial net fluid secretion of surviving ductal cells. However, the improvement in the
efficiency of transepithelial fluid secretion may be of
limited value if the noxa patogena holds over the
response of normal tissue is the production of fibrosis
that results in to the complete loss of tissue function.
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Therefore, drugs capable of reducing the fibrinogenic
potential of specific treatments are of value in clinical
setting.
Some authors documented that DNA methylation
exert epigenetic control over fribrinogenesis and wound
healing. These events need a process of cell transdifferentiation of resident cells to stellate cells, a particular
subtype of myofibroblast, which seems to be a common
process in the majority of soft tissues. Myofibroblasts
are highly profibrinogenic and produce proinflammatory
mediators (IL-6, MCP-1, PFGF, TGFb-1) resulting in
the secretion of a large quantities of collagen I and III
[171]. MeCP2 is a methyl-CpG-binding protein that has
the potential to exert regulation over the expression of
multiple genes via its interaction with methylated DNA.
MeCP2 is a repressor of IkBa which is required for
transdifferentiation and profibrinogenic activity of stellate cells. Another important mediator of transdifferentiation and fribrinogenesis is PPARg whose
transcriptional silencing activity is required for conversion of hepatic stellate cells to myofibroblast [172].
Forced expression of PPARg in hepatic myofibroblast
results in reversing the transdifferentiation and profibrinogenic potential of stellate cells with down-regulation
of type I collagen, loss of proliferation, and reacquisition
of their adipogenic characteristics. Experimental data
suggest that MeCP2 is recruited to the IkBa promoter
and decitabine treatment modulating epigenetically the
expression these mediator exerts control over key fibrinogenic and inflammatory transcriptional regulators
reducing greatly the fibrogenic potential of stellate cells
[173].
Another significant property of DNMT inhibitors is
their capability to act as antioxidants under specific biological setting. This property is very important, especially in conditions where an excess of free radicals
results in tissue damage. EGCG is a major element of
green tea with a documented activity as DNMT inhibitor. Conflicting data are available in literature on the
effect of EGCG on normal and tumoral cells. In an
immortalized normal breast epithelial cell line
(MCF10A), EGCG induced growth arrest prior to the
cell cycle restriction point, with elevated p21, hypophosphorylation of Rb, and decreased cyclin D1, suggesting
that higher concentrations of EGCG may be toxic to
normal mammary epithelial cells [174]. However, EGCG
may have both antioxidant and prooxidative activities
involved in redox cycling and quinone formation [175]
and may induce oxidative stress in vivo [176,177].
Cysteine conjugates, indicative of reactive species development, have been detected after 200 and 400 mg/kg i.
p. EGCG [178]. EGCG was also reported to be capable
of inducing liver, kidney and gastrointestinal toxicity
which seemed to be correlated with bioavailability of

Page 10 of 16

EGCG [176,179]. Different results were documented by
Yamamoto and his group [180] since new mechanisms
by which EGCG may act differentially in tumor and
normal cells were identified. In humans, EGCG is
rapidly absorbed through the oral mucosa and secreted
back into the oral cavity by saliva, suggesting that salivary glandular cells may tolerate high concentrations of
EGCG [181]. Accordingly, this evidence suggests that
EGCG may differentially affect oxidative status and may
act as either a ROS inducer or a ROS suppressor
depending upon the cell type [182]. EGCG concentrations higher than plasma Cmax do not produce ROS in
cells derived from the normal epidermis and oral cavity
but rather protect these cells by decreasing ROS production. Mechanisms responsible for the differential
effects could rely on distinctive signal pathways activated
by EGCG in a tissue-specific manner. High concentration of EGCG failed to produce ROS in normal epidermal keratinocytes, and immortalized normal salivary
gland cells. In contrast, EGCG elevated ROS levels upon
treatment in a dose-dependent manner in oral carcinoma cells. The ROS levels were significantly higher in
the tumor cell lines that possessed low catalase activity.
Therefore, EGCG may potentially simultaneously
enhance tumor cell death rate and protect normal cells
from chemo/radiation-induced oxidative stress in
tumors such as skin and head neck [182].
If uncertainty exists regarding the effect of DNMT
inhibitors on normal tissues, scanty direct evidence
exists regarding the biological effects these inhibitors
have in combination with chemotherapy or ionizing
radiation. Clinical data indicate that, when decitabine is
administered in association with cisplatin in subjects
with advanced squamous cell carcinoma of the cervix, a
significant hematological toxicity is documented [183].
Recent study reported interesting evidence of biological interaction of a DNMT inhibitor with chemotherapy.
In this report 5-Aza was combined with cisplatin in
order to measure the improvement in the therapeutic
index of these two drugs. Interestingly, 5-Aza prevented
the nephrotoxicity related to cisplatin, which was further
related with the lowering in the levels of BUN and creatinine in the murine model. The mechanism by which
5-Aza decreased the nephrotoxicity involved the reduction of the levels of mediators such as metallothioneins,
which are able to induce oxidative stress or indirectly
activate gene responsible for preventing oxidative stress.
This represents the first evidence that an epigenetic
treatment with a DNMT inhibitor reduces the toxicity
related to chemotherapy [184]. A single study dealing
with the combination of decitabine with ionizing radiation reports in a differentiated effect in terms of growth
inhibition normal and cancerous cells [185]. When decitabine was combined with radiation no significant
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synergism in terms of growth inhibition was found on
human fibroblasts. On contrary, irradiation alone
resulted in a significant decrease in the proliferation of
normal fibroblasts, suggesting that decitabine significantly modified cellular response to irradiation.
Off-target effects of DNMT inhibitors and potential
contribution to radiosensitization

The mechanisms by which DNMT inhibitors exert their
effects on cells may be divided into those related to
DNMT inhibitors and those not related to demethylation of DNA. The latter mechanisms may be defined as
off-target effects and although observed at higher concentrations may substantially contribute to the antitumor properties of nucleoside analogues alone or in
combination with chemotherapy or ionizing radiation.
Numerous chemicals as well as radiation can lead to
covalent protein-DNA adducts. 5-Aza, one of the most
important nucleoside analogue, leads to protein-DNA
adducts. 5-Aza is a cytidine analogue in which carbon-5
(C5) of the pyrimidine ring is replaced with nitrogen.
Normally, a DNA cytosine-C5 methyltransferase
(MTase) acts on cytosine residue in its recognition
sequence by covalent binding to C6, and then transferring the methyl group from S-adenosylmethionine to
C5; the covalent protein-DNA adduct is then reversed
and the enzyme dissociates from the DNA [186]. 5-Aza
substitution at target cytosine interferes with the reaction cycle and results in long-lived or irreversible
MTase-DNA adduct. A major consequence of 5-Aza
treatment is loss of cytosine MTase activity [186]. In
mammalian cells, 5-Aza results in defective tRNA and
rRNAs and inhibits protein synthesis [187]. Additionally,
decitabine results in the induction of p53 DNA damage
response, proposed to be dependent on formation of
MTase adducts [188]. Covalent protein-DNA adducts or
tightly bound proteins represent a major challenge to
the DNA replication machinery. DNA replication forks
can be blocked in vivo by replication termination complexes [189]. As previously described, scanty evidences
indicate that nucleoside analogues may be efficient
radiosensitizers. The cytotoxic mechanisms of nucleoside analogues may potentiate the effects of ionizing
radiation for several theoretical reasons. First, as DNA
synthesis inhibitors, nucleoside analogues have a potential to inhibit the repair of genomic damage induced by
ionizing radiation. Second, because they are preferentially cytotoxic to proliferative cells, these analogues may
decrease the number of tumor clonogens and thus slow
down cell repopulation during fractionated radiotherapy.
Tumor shrinkage induced by these compounds may
improve tumor oxygenation and counter the detrimental
effect of tumor hypoxia on radiation response. Third, a
nucleoside analogue with DNA chain terminator
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property may, following their incorporation into the
DNA repair patch, trigger an apoptotic response similar
to that observed during the replication phase. Since
DNA damage is induced in all phase of the cell cycle by
radiation, this mechanism offers the prospect of extending the cytotoxicity of these analogues to non-S-phase
cells. Due to the very low number of studies facing this
topic the aforementioned mechanisms are all putative
and specific experimental studies in vitro and in vivo
settings should be performed in order to confirm these
hypotheses.
Combination of DNMT inhibitors with HDAC inhibitors

Due to their relative antitumor selectivity DNMT inhibitors have been used in combination with HDAC inhibitors. Recently, there have been several excellent reviews
of the histone deacetylase inhibitors (HDACIs) field
used as a therapeutic option alone or in association with
a variety of novel and conventional anticancer agents
[190-192]. Optimal re-expression of methylated genes
such as tumor suppressor or other cancer relevant genes
following the serial application of a DNA methyltransferase inhibitor followed by an HDAC inhibitor created
significant interest in combination epigenetic therapy.
Among these p16INK4A and p14INK4b, Apaf-1 and
caspase-8 are efficiently re-expressed when DNMT inhibitors and HDACIs are combined [190-192]. DNMT
and a group of methyl-cytosine binding proteins, e.g.,
MeCP2, can also recruit and direct HDACs to the chromatin associated with silenced genes. Combined treatment with a DNMT inhibitor and HDACI has been
shown to be superior in de-repressing silenced tumor
suppressor genes, as well as in inducing increased
growth inhibition, differentiation and apoptosis of cancerous cells. The best results in de-repressing silenced
genes are observed when DNMT inhibitors are used
first at relatively low doses followed by exposure to the
HDACIs.

Conclusions and Future Directions
No doubt exists that combining traditional cancer therapy with epigenetic modulators and reversing the
changes of DNA methylation pattern holds a huge
potential for successful treatment of haematological and
solid malignancies. There are a number of important
steps that need to be accomplished on the path towards
efficient epigenetic therapy. Firstly, it is important to
gain more insight into the diverse molecular mechanisms of the epi-drugs available today. A body of experimental evidences suggests that DNMT inhibitors may
serve as efficient chemo- and radiosensitizers in solid
tumors. However, the observation reported need more
support in order to indicate intimate molecular mechanisms of chemo- and radiosensitization. Additionally, the
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understanding of different mechanisms as well as the
long term safety of DNMT inhibitors on normal cells
alone or in combination with standard treatments
remains very limited and requires further research
efforts. Although clinical and preclinical data indicate a
substantial toxicity of these inhibitors, other evidence
seems to suggest that these drugs may have potential in
reducing toxicity under specific conditions. Therefore,
the future goal is to indentify compounds able to
enhance the therapeutic index and protect the non
malignant tissues from side effects. Finally, other preclinical data suggest that the sensitizing effects of DNMT
inhibitors seem to depend on the epigenetic modulation
of a wide array of genes. A non negligible part of this
effect may be related to the off-target mechanisms.
Future research will focus on establishing clinically relevant combinations of DNMT inhibitors and conventional cancer therapies. In particular, a longstanding
interest exists in the development of molecules that can
modify cellular responses to radiation and chemotherapy. The future perspectives lie in identifying more similar compounds and elucidating their mechanisms of
action in order to develop more effective cancer therapies and treatments.
Acknowledgements
The authors wish to express the gratitude to Dr. Mario Di Staso (Division of
Radiotherapy, San Salvatore Hospital, L’Aquila), Dr. Pierluigi Bonfili (Division of
Radiotherapy, San Salvatore Hospital, L’Aquila), and Dr. Mario Tombolini
(Department of Otorhinolaryngology, Audiology and Phoniatrics ‘G. Ferreri’,
University ‘La Sapienza’, Rome, Italy) for critical review and helpful discussion
with the manuscript.

Page 12 of 16

4.

5.
6.
7.
8.
9.
10.

11.
12.
13.
14.

15.
16.

17.

18.
19.
20.

21.
Author details
1
Department of Experimental Medicine, Division of Radiation Oncology,
S. Salvatore Hospital, L’Aquila, University of L’Aquila, Medical School, L’Aquila
67100, Italy. 2Department of Experimental Medicine, Laboratory of
Radiobiology, University of L’Aquila, Medical School, L’Aquila 67100, Italy.
3
Department of Cancer Biology and Medical Oncology, Kimmel Cancer
Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.

22.

23.
Authors’ contributions
GLG, CF, FM, RGP and VT drafted and wrote the manuscript. VP and BMZ
revised the manuscript critically for important and intellectual content. GLG
and FM supervised the project. All authors read and approved the final
manuscript.

24.
25.

Competing interests
The authors declare that they have no competing interests.
26.
Received: 18 February 2010 Accepted: 25 November 2010
Published: 25 November 2010
References
1. Horn PJ, Peterson CL: Heterochromatin assembly: A new twist on an old
model. Chromosome Res 2006, 14:83-94.
2. Luger K: Structure and dynamic behavior of nucleosomes. Curr Opin
Genet Dev 2003, 13:127-135.
3. Saha A, Wittmeyer J, Cairns BR: Chromatin remodelling: The industrial
revolution of DNA around histones. Nat Rev Mol Cell Biol 2006, 7:437-47.

27.

28.

Marks PA, Rifkind RA, Richon VM, Breslow R: Inhibitors of histone
deacetylase are potentially effective anticancer agents. Clin Cancer Res
2001, 7:759-60.
Iizuka M, Smith MM: Functional consequences of histone modifications.
Curr Opin Genet Dev 2003, 13:154-60.
Spotswood HT, Turner BM: An increasingly complex code. J Clin Invest
2002, 110:577-82.
Bird A: DNA methylation patterns and epigenetic memory. Genes Dev
2002, 16:6-21.
Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer.
Nat Rev Genet 2002, 3:415-428.
Bestor TH: The DNA methyltransferases of mammals. Hum Mol Genet
2000, 9:2395-2402.
Okano M: DNA methyltransferases Dnmt3a and Dnmt3b are essential for
de novo methylation and mammalian development. Cell 1999,
99:247-257.
Okano M: Cloning and characterization of a family of novel mammalian
DNA (cytosine-5) methyltransferases. Nat Genet 1998, 19:219-220.
Rhee I: DNMT1 and DNMT3b cooperate to silence genes in human
cancer cells. Nature 2002, 416:552-556.
Rhee I: CpG methylation is maintained in human cancer cells lacking
DNMT1. Nature 2000, 404:1003-1007.
Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, De Vito M:
Chronic Azacitidine Treatment Results in Differentiating Effects,
Sensitizes Against Bicalutamide in Androgen-Independent Prostate
Cancer Cells. The Prostate 2008, 68:793-801.
Herman JG, Baylin SB: Gene silencing in cancer in association with
promoterhypermethylation. N Engl J Med 2003, 349:2042-2054.
Silverman LR, Demakos EP, Peterson BL: Randomized controlled trial of
azacitidine in patients with the myelodysplastic syndrome: a study of
the cancer and leukemia group B. J Clin Oncol 2002, 20:2429-40.
Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB: Synergy of
demethylation and histone deacetylase inhibition in the re-expression of
genes silenced in cancer. Nat Genet 1999, 21:103-7.
kristensen LS, Nielsen HM, Hansen LL: Epigenetic and cancer treatment.
European Juornal of Pharmacology 2009, 625:131-142.
Oki Y, Aoki E, Issa JP: Decitabine–Bedside to bench. Crit Rev Oncol 2007,
61:140-152.
Larsen AK, Escargueil AE, Skladanowski A: Resistance mechanisms
associated with altered intracellular distribution of anticancer agents.
Pharmacol Ther 2000, 85:217-29.
Larsen AK, Skladanowski A: Cellular resistance to topoisomerase-targeted
drugs: from drug uptake to cell death. Biochim Biophys Acta 1998,
1400:257-74.
Kern MA, Helmbach H, Artuc M, Karmann D, Jurgovsky K, Schadendorf D:
Human melanoma cell lines selected in vitro displaying various levels of
drug resistance against Cisplatin, fotemustine, vindesine or Etoposide:
modulation of proto-oncogene expression. Anticancer Res 1997,
17:4359-70.
Spitz DR, Kinter MT, Roberts RJ: Contribution of increased glutathione
content to mechanisms of oxidative stress resistance in hydrogen
peroxide resistant hamster fibroblasts. J Cell Physiol 1995, 165:600-9.
Spitz DR, Li GC: Heat-induced cytotoxicity in H2O2-resistant Chinese
hamster fibroblasts. J Cell Physiol 1990, 142:255-60.
Spitz DR, Phillips JW, Adams DT, Sherman CM, Deen DF, Li GC: Cellular
resistance to oxidative stress is accompanied by resistance to Cisplatin:
the significance of increased catalase activity and total glutathione in
hydrogen peroxide-resistant fibroblasts. J Cell Physiol 1993, 156:72-9.
Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA,
Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV:
Identification of a candidate tumour suppressor gene, MMAC1, at
chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat
Genet 1997, 15:356-362.
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C,
Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B,
Hibshoosh H, Wigler MH, Parsons R: PTEN, a putative protein tyrosine
phosphatase gene mutated in human brain, breast, and prostate cancer.
Science 1997, 275:1943-1947.
Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D, Parsons R: PTEN, a
putative protein tyrosine phosphatase gene mutated in human brain,
breast, and prostate cancer. Cancer Res 1997, 57:4183-4186.

Gravina et al. Molecular Cancer 2010, 9:305
http://www.molecular-cancer.com/content/9/1/305

29. Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J:
Disruption of the MMAC1/PTEN gene by deletion or mutation is a
frequent event in malignant melanoma. Cancer Res 1997, 57:3660-3663.
30. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J,
Isaacs WB, Bova GS, Sidransky D: Frequent inactivation of PTEN/MMAC1 in
primary prostate cancer. Cancer Res 1997, 57:4997-5000.
31. Gravina G, Biordi L, Martella F, Flati V, Ricevuto E, Ficorella C, Tombolini V,
Festuccia C: Epigenetic modulation of PTEN expression during
antiandrogenic therapies in human prostate cancer. International Journal
of Oncology 2009, 35:1133-9.
32. Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, Liu DD, Kurie JM, Mao L,
Khuri FR: Lack of PTEN Expression in Non-Small Cell Lung Cancer Could
Be Related to Promoter Methylation. Clin Cancer Res 2002, 8:1178-1184.
33. Whang YE, Wu X, Suzuki H: Inactivation of the tumor suppressor
PTENyMMAC1 in dvanced human prostate cancer through loss of
expression. Proc Natl Acad Sci 1998, 95:5246-5250.
34. Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ: Regulation of AKT/
PKB activity, cellular growth, and apoptosis in prostate carcinomacells
by MMAC/PTEN. Cancer Res 1999, 59:2551-2556.
35. Festuccia C, Gravina GL, D’Alessandro AM, Muzi P, Millimaggi D: Azacitidine
improves antitumor effects of docetaxel and cisplatin in aggressive
prostate cancer models. Endocr Relat Cancer 2009, 16:401-413.
36. Tanaka Motoyoshi, Koul Dimpy, Davies AMichael, Liebert Monica,
Steck APeter, Grossman HBarton: MMAC1/PTEN inhibits cell growth and
induces chemosensitivity to doxorubicin in human bladder cancer cells.
Oncogene 2000, 19:5406-5412.
37. Fujiwara T, Grimm EA, Mukhopadnyay T, Zhang WW: Induction of
chemosensitivity in human lung cancer cells in vivo by adenovirusmediated transfer of the wild type p53 gene. Cancer Res 1994,
54:2287-2291.
38. Ogawa N, Fujiwara T, Kagawa S: Novel combination therapy for human
colon cancer with adenovirus-mediated wild-type p53 gene transfer and
DNA-damaging chemotherapeutic agent. Int J Cancer 1997, 73:367-70.
39. Gurnani M, Lipari P, Dell J, Shi B, Nielsen LL: Adenovirus-mediated p53
gene therapy has greater efficacy when combined with chemotherapy
against human head-neck, ovarian, prostate, and breast cancer. Cancer
Chemother Pharmacol 1999, 44:143-151.
40. Thoretsky JA, Takar M, Eskenazi AE, Frantz CN: Phosphoinositide 3hydroxide kinase blockade enhances apoptosis in the Ewing’s sarcoma
family tumors. Cancer Res 1999, 59:5745-50.
41. Wan X, Li J, Lu X: PTEN augments doxorubicin-induced apoptosis in
PTEN-null Ishikawa cells. Int J Gynecol Cancer 2007, 17:808-812.
42. Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB: PTEN protects
p53from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem
2002, 277:5484-9.
43. Green SK, Frankel A, Kerbel RS: Adhesion-dependent multicellular drug
resistance. Anti-Cancer Drug Design 1999, 14:153-68.
44. St Croix B, Rak JW, Kapitain S, Sheehan C, Graham CH, Kerbel RS: Reversal
by hyaluronidase of adhesion-dependent multicellular drug resistance in
mammary carcinoma cells. J Natl Cancer Inst 1996, 88:1285-96.
45. St Croix B, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM,
Kerbel RS: Impact of the cyclin dependent kinase inhibitor p27Kip1 on
adhesion-dependent resistance of tumor cells to anticancer agents. Nat
Med 1996, 2:1204-10.
46. St Croix B, Sheehan C, Rak JW, Florenes VA, Slingerland JM, Kerbel RS: Ecadherin-dependent growth suppression is mediated by the cyclin
dependent kinase inhibitor p27KIP1. J Cell Biol 1998, 142:557-71.
47. Green SK, Francia G, Isidoro C, Kerbel RS: Anti-adhesive antibodies
targeting E-cadherin sensitize multicellular tumor spheroids to
chemotherapy in vitro. Mol Cancer Ther 2004, 3:149-59.
48. Teicher BA, Herman TS, Holden SA, Wang YY, Pfeffer MR, Crawford JW,
Frei E: Tumor resistance to alkylating agents conferred by mechanisms
operative only in vivo. Science 1990, 247:1457-61.
49. Youn CK, Cho HJ, Kim SH, Kim HB, Kim MH, Chang IY, Lee JS, Chung MH,
Hahm KS, You HJ: Bcl-2 expression suppresses mismatch repair activity
through inhibition of E2F transcriptional activity. Nat Cell Biol 2005,
7:137-47.
50. Kobayashi H, Man S, Kapitain SJ, Teicher BA, Kerbel RS: Acquired
multicellular-mediated resistance to alkylating agents in cancer. Proc Natl
Acad Sci USA 1993, 90:3294-8.

Page 13 of 16

51. Jain RK: Delivery of novel therapeutic agents in tumors: physiological
barriers and strategies. J Natl Cancer Inst 1989, 81:570-6.
52. Bindra RS, Schaffer PJ, Meng A, Woo J, Måseide K, Roth ME, Lizardi P,
Hedley DW, Bristow RG, Glazer PM: Down-regulation of Rad51 and
decreased homologous recombination in hypoxic cancer cells. Mol Cell
Biol 2004, 24:8504-18.
53. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R: Reversal of drug
resistance in human tumor xenografts by 2V-deoxy-5azacytidineinduced demethylation of the hMLH1 gene promoter. Cancer
Res 2000, 60:6039-44.
54. Chan AT, Tao Q, Robertson KD, Flinn IW, Mann RB, Klencke B, Kwan WH,
Leung TW, Johnson PJ, Ambinder RF: Azacitidine induces demethylation
of the Epstein-Barr virus genome in tumors. J Clin Oncol 2004, 22:1373-81.
55. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG: Inactivation of
the DNArepair geneO6-methylguanine-DNA methyltransferase by
promoter hypermethylation is a common event in primary human
neoplasia. Cancer Res 1999, 59:793-797.
56. Esteller M, Herman JG: Generating mutations but providing
chemosensitivity: the role of O6-methylguanine DNA methyltransferase
in human cancer. Oncogene 2004, 23:1-8.
57. Hermann A, Gowher H, Jeltsch A: Biochemistry and biology of
mammalian DNA methyltransferases. Cell Mol Life Sci 2004, 61:2571-2587.
58. Bae SI, Lee HS, Kim SH, Kim WH: Inactivation of O6-methylguanine-DNA
methyltransferase by promoter CpG island hypermethylation in gastric
cancers. Br J Cancer 2002, 86:1888-1892.
59. Danam RP, Howell SR, Brent TP, Harris LC: Epigenetic regulation ofO6methylguanine-DNA methyltransferase gene expression by histone
acetylation and methyl-CpG binding proteins. Mol Cancer Ther 2005,
4:1-69.
60. Wang W, Huper G, Guo Y, Murphy SK, Olson JA Jr, Marks JR: Analysis of
methylation sensitive transcriptome identifies GADD45a as a frequently
methylated gene in breast cancer. Oncogene 2005, 24:705-2714.
61. Michel B, Flores MJ, Viguera E, Grompone G, Seigneur M, Bidnenko V:
Rescue of arrested replication forks by homologous recombination. Proc
Natl Acad Sci USA 2001, 98:8181-8.
62. McGlynn P, Lloyd RG: Recombinational repair and restart of damaged
replication forks. Nat Rev Mol Cell Biol 2002, 3:859-70.
63. Szostak JW, Orr-Weaver TL, Rothstein RJ, Stahl FW: The doublestrand-break
repair model for recombination. Cell 1983, 33:25-35.
64. Fishman-Lobell J, Rudin N, Haber JE: Two alternative pathways of doublestrand break repair that are kinetically separable and independently
modulated. Mol Cell Biol 1992, 12:1292-303.
65. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ: ATM phosphorylates
histone H2AX in response to DNA double-strand breaks. J Biol Chem
2001, 276:42462-7.
66. Rothkamm K, Kruger I, Thompson LH, Lobrich M: Pathways of DNA
double-strand break repair during the mammalian cell cycle. Mol Cell Biol
2003, 23:5706-15.
67. Durocher D, Jackson SP: DNA-PK, ATM and ATR as sensors of DNA
damage: variations on a theme? Curr Opin Cell Biol 2001, 13:225-31.
68. Roos WP, Kaina B: DNA damage-induced cell death by apoptosis. Trends
Mol Med 2006, 12:440-50.
69. Kurz EU, Douglas P, Lees-Miller SP: Doxorubicin activates ATM dependent
phosphorylation of multiple downstream targets in part through the
generation of reactive oxygen species. J Biol Chem 2004, 279:53272-81.
70. Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H: 5-Azacytidine, a DNA
methyltransferase inhibitor, induces ATR-mediated DNA double-strand
break responses, apoptosis, and synergistic cytotoxicity with
doxorubicine and bortezomib against multiple myeloma cells. Mol
Cancer Ther 2007, 6:1718-1727.
71. Taylor WR, Stark GR: Regulation of the G2/M transition by p53. Oncogene
2001, 20:1803-15.
72. Wichmann A, Jaklevic B, Su TT: Ionizing radiation induces caspase
dependent but Chk2- and p53-independent cell death in Drosophila
melanogaster. Proc Natl Acad Sci USA 2006, 103:9952.
73. Aliouat-Denis CM, Dendouga N, Van den Wyngaert I, Goehlmann H,
Steller U, van de Weyer I, Van Slycken N, Andries L, Kass S, Luyten W,
Janicot M, Vialard JE: p53-independent regulation of p21Waf1/Cip1
expression and senescence by Chk2. Mol Cancer Res 2005, 3:627-34.
74. Pepper CJ, Hambly RM, Fegan CD, Delavault P, Thurston DE: The novel
sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has

Gravina et al. Molecular Cancer 2010, 9:305
http://www.molecular-cancer.com/content/9/1/305

75.

76.

77.

78.

79.

80.

81.

82.

83.

84.

85.

86.

87.
88.

89.

90.

91.

92.

potent and selective in vitro cytotoxicity in human B-cell chronic
lymphocytic leukemia cells with evidence of a p53-independent
mechanism of cell kill. Cancer Res 2004, 64:6750-5.
Tse AN, Schwartz GK: Potentiation of cytotoxicity of topoisomerase in
poison by concurrent and sequential treatment with the checkpoint
inhibitor UCN-01 involves disparate mechanisms resulting in either p53independent clonogenic suppression or p53-dependent mitotic
catastrophe. Cancer Res 2004, 64:6635-44.
Chai Guolin, Li Lian, Zhou Wen, Wu Lipeng, Zhao Ying, Wang Donglai,
Lu Shaoli, Yu Yu, Wang Haiying, McNutt AMichael, Hu Ye-Guang,
Chen Yingqi, Yang Yang, Wu Xin, Otterson AGregory, Zhu Wei-Guo: HDAC
Inhibitors Act with 5-aza-2’-Deoxycytidine to Inhibit Cell Proliferation by
Suppressing Removal of Incorporated Abases in Lung Cancer Cells. PLoS
One 2008, 3:,3412-20.
Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P,
Alvarez R, Schiavone EM, Ferrara F, Bresciani F, Weisz A, de Lera AR,
Gronemeyer H, Altucci L: Tumor-selective action of HDAC inhibitors
involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005,
11:77-84.
Xu J, Zhou JY, Tainsky MA, Wu GS: Evidence that Tumor Necrosis FactorRelated Apoptosis-Inducing Ligand Induction by 5-Aza-2¶-Deoxycytidine
Sensitizes Human Breast Cancer Cells to Adriamycin. Cancer Res 2007,
67:1203-1211.
Wang Q, Wang X, Hernandez A, Hellmich MR, Gatalica Z, Evers BM:
Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/
GSK-3 pathway in human colon cancer cells. J Biol Chem 2002,
277:36602-10.
Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B,
Debatin KM: Sensitization for death receptor- or drug-induced apoptosis
by re-expression of caspase-8 through demethylation or gene transfer.
Oncogene 2001, 20:5865-77.
Fulda S, Debatin KM: 5-Aza-2¶-deoxycytidine and IFN-gamma cooperate
to sensitize for TRAIL-inducedapoptosis by upregulating caspase-8.
Oncogene 2006, 25:5125-33.
Gomyo Y, Sasaki J, Branch C, Roth JA, Mukhopadhyay T: 5-aza-2¶deoxycytidine upregulates caspase-9 expression cooperating with p53induced apoptosis in human lung cancer cells. Oncogene 2004,
23:6779-87.
Nottoli T, Hagopian-Donaldson S, Zhang J, Perkins A, Williams T: AP-2-null
cells disrupt morphogenesis of the eye, face, and limbs in chimeric
mice. Proc Natl Acad Sci USA 1998, 95:13714-9.
Feng W, Williams T: Cloning and characterization of the mouse AP-2e
gene: a novel family member expressed in the developing olfactory
bulb. Mol Cell Neurosci 2003, 24:460-75.
Higler-Eversheim K, Moser M, Schorle H, Buettner R: Regulatory roles of
AP-2 transcription factors in vertebrate development, apoptosis and cell
cycle control. Gene 2000, 260:1-12.
McPherson LA, Loktev AV, Weigel RJ: Tumor suppressor activity of AP2a
mediated through a direct interaction with p53. J Biol Chem 2002,
277:45028-33.
Zeng YX, Somasundaram K, El-Deiry WS: AP2 inhibits cancer cell growth
and activates p21WAF1/CIP1 expression. Nat Genet 1997, 15:28-32.
Wajapeyee N, Somasundaram K: Cell cycle arrest and apoptosis induction
by activator protein 2a (AP-2a) and the role of p53 and p21WAF1/CIP1
in AP-2amediated growth inhibition. J Biol Chem 2003, 278:52093-101.
Zhang J, Brewer S, Huang J, Williams T: Overexpression of transcription
factor AP-2a suppresses mammary gland growth and morphogenesis.
Dev Biol 2003, 256:127-45.
Douglas DB, Akiyama Y, Carraway H: Hypermethylation of a small
CpGuanine rich region correlates with loss of activator protein-2a
expression during progression of breast cancer. Cancer Res 2004,
64:1611-20.
Anttila MA, Kellokoski JK, Moisio KI, Mitchell PJ, Saarikoski S, Syrjänen K,
Kosma VM: Expression of transcription factor AP-2a predicts survival in
epithelial ovarian cancer. Br J Cancer 2000, 82:1974-83.
Ropponen KM, Kellokoski JK, Pirinen RT, Moisio KI, Eskelinen MJ, Alhava EM,
Kosma VM: Expression of transcription factor AP-2 in colorectal
adenomas and adenocarcinomas; comparison of immunohistochemistry
and in situ hybridisation. J Clin Pathol 2001, 54:533-8.

Page 14 of 16

93. Heimberger AB, McGary EC, Suki D, Ruiz M, Wang H, Fuller GN, Bar-Eli M:
Loss of the AP-2a transcription factor is associated with the gradeof
human gliomas. Clin Cancer Res 2005, 11:267-72.
94. Ruiz M, Pettaway C, Song R, Stoeltzing O, Ellis L, Bar-Eli M: Activator protein
2a inhibits tumorigenicity and represses vascular endothelial growth
factortranscription in prostate cancer cells. Cancer Res 2004, 64:631-8.
95. Gershenwald JE, Sumner W, Calderone T, Wang Z, Huang S, Bar-Eli M:
Dominant-negative transcription factor AP-2 augments SB-2 melanoma
tumor growthin vivo. Oncogene 2001, 20:3363-75.
96. Dicato M, Duhem C, Pauly M, Ries F: Multidrug resistance: molecular and
clinical aspects. Cytokines Cell Mol Ther 1997, 3:91-9.
97. Hunt CR, Sim JE, Sullivan SJ, Featherstone T, Golden W, Von Kapp-Herr C,
Hock RA, Gomez RA, Parsian AJ, Spitz DR: Genomic instability and catalase
gene amplification induced by chronic exposure to oxidative stress.
Cancer Res 1998, 58:3986-92.
98. Bergelson S, Pinkus R, Daniel V: Intracellular glutathione levels regulate
Fos/Jun induction and activation of glutathione S-transferase gene
expression. Cancer Res 1994, 54:36-40.
99. Dewey WC: Arrhenius relationships from the molecule and cell to the
clinic. Int J Hyperthermia 1994, 10:457-83.
100. Diamond DA, Parsian A, Hunt CR, Lofgren S, Spitz DR, Goswami PC, Gius D:
Redox factor-1 (Ref-1) mediates the activation of AP-1 in HeLa and NIH
3T3 cells in response to heat shock. J Biol Chem 1999, 274:16959-64.
101. Kerppola T, Curran T: Transcription. Zen and the art of Fos and Jun.
Nature 1995, 373:199-200.
102. Martins NM, Santos NA, Curti C, Bianchi ML, Santos AC: Cisplatin induces
mitochondrial oxidative stress with resultant energetic metabolism
impairment, membrane rigidification and apoptosis in rat liver. J Appl
Toxicol 2007, 23:234-244.
103. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ: Spitz DR. 2-DeoxyDglucose combined with cisplatin enhances cytotoxicity via metabolic
oxidative stress in human head and neck cancer cells. Cancer Res 2007,
67:3364-70.
104. Siitonen T, Alaruikka P, Mantymaa P, Savolainen ER, Kavanagh TJ, Krejsa CM,
Franklin CC, Kinnula V, Koistinen P: Protection of acute myeloblastic
leukemia cells against apoptotic cell death by high glutathione and
gammaglutamylcysteine synthetase levels during etoposide-induced
oxidative stress. Ann Oncol 1999, 10:1361-7.
105. Mairesse N, Bernaert D, Del Bino G, Horman S, Mosselmans R, Robaye B,
Galand P: Expression of HSP27 results in increased sensitivity to tumor
necrosis factor, etoposide, and H2O2 in an oxidative stress-resistant cell
line. J Cell Physiol 1998, 177:606-17.
106. Furuta Y, Hunter N, Barkley T, Hall E, Milas L: Increase in radioresponse of
murine tumors by treatment with indomethacin. Cancer Res 1988,
48:3008-13.
107. Iliakis G, Seaner R, Okayasu R: Effects of hyperthermia on the repair of
radiation-induced DNA single- and double-strand breaks in DNA doublestrand break repair-deficient and repair-proficient cell lines. Int J
Hyperthermia 1990, 6:813-33.
108. Jurivich DA, Pachetti C, Qiu L, Welk JF: Salicylate triggers heat shock factor
differently than heat. J Biol Chem 1995, 270:24489-95.
109. Jurivich DA, Sistonen L, Kroes RA, Morimoto RI: Effect of sodium salicylate
on the human heat shock response. Science 1992, 255:1243-5.
110. Bhushan A, Abramson R, Chiu JF, Tritton TR: Expression of c-fos in human
and murine multidrug-resistant cells. Mol Pharmacol 1992, 42:69-74.
111. Dignam JD: Preparation of extracts from higher eukaryotes. Methods
Enzymol 1990, 182:194-203.
112. Maity A, Kao GD, Muschel RJ, McKenna WG: Potential molecular targets
for manipulating the radiation response. Int J Radiat Oncol Biol Phys 1997,
37:639-53.
113. Yao KS, Godwin AK, Johnson SW, Ozols RF, O’Dwyer PJ, Hamilton TC:
Evidence for altered regulation of gamma-glutamylcysteine synthetase
gene expression among cisplatin-sensitive and cisplatin-resistant human
ovarian cancer cell lines. Cancer Res 1995, 55:4367-74.
114. Bradbury CM, Locke JE, Wei SJ, Shah S, Rene LM, Clemens RA, Roti Roti J,
Horikoshi N, Gius D: Increased activator protein 1 activity as well as
resistance to heat-induced radiosensitization, hydrogen peroxide, and
cisplatin are inhibited by indomethacin in oxidative stress-resistant cells.
Cancer Res 2001, 61:3486-92.
115. Mishra MV, Bisht K S, Sun L, Muldoon-Jacobs K, Awwad R, Kaushal A,
Nguyen P, Huang L, Pennington JD, Markovina S, Bradbury CM, Gius D:

Gravina et al. Molecular Cancer 2010, 9:305
http://www.molecular-cancer.com/content/9/1/305

116.

117.

118.

119.

120.
121.

122.

123.

124.

125.

126.
127.
128.
129.

130.

131.

132.

133.

134.

135.

136.

DNMT1 as a Molecular Target in a Multimodality-Resistant Phenotype in
Tumor Cells. Mol Cancer Res 2008, 6:243-249.
Qiu H, Yashiro M, Shinto O, Matsuzaki T, Hirakawa K: DNA
methyltransferase inhibitor 5-aza-CdR enhances the radiosensitivity of
gastric cancer cells. Cancer Sci 2009, 1:181-188.
Santi DV, Norment A, Garrett CE: Covalent bond formation between a
DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc
Natl Acad Sci USA 1984, 81:6993-7.
Friedman S: The irreversible binding of azacytosine-containing DNA
fragments to bacterial DNA(cytosine-5)methyltransferases. J Biol Chem
1985, 260:5698-705.
Gabbara S, Bhagwat AS: The mechanism of inhibition of DNA (cytosine-5)-methyltransferases by 5-azacytosine is likely to involve methyl transfer
to the inhibitor. Biochem J 1995, 307:87-92.
Friedman S, Som S: Induction of EcoRII methyltransferase: evidence for
autogenous control. J Bacteriol 1993, 175:6293-8.
Liu K, Wang YF, Cantemir C, Muller MT: Endogenous assays of DNA
methyltransferases: evidence for differential activities of DNMT1,
DNMT2, and DNMT3 in mammalian cells in vivo. Mol Cell Biol 2003,
23:2709-19.
Juttermann R, Li E, Jaenisch R: Toxicity of 5-aza-2deoxycytidine to
mammalian cells is mediated primarily by covalent trapping of DNA
methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA
1994, 91:11797-801.
Ferguson AT, Vertino PM, Spitzner JR, Baylin SB, Muller MT, Davidson NE:
Role of estrogen receptor gene demethylation and DNA
methyltransferase DNA adduct formation in 5-aza-2¶-deoxycytidineinduced cytotoxicity in human breast cancer cells. J Biol Chem 1997,
272:32260-6.
Karpf AR, Moore BC, Ririe TO, Jones DA: Activation of the p53 DNA
damage response pathway after inhibition of DNA methyltransferase by
5-aza-2-deoxycytidine. Mol Pharmacol 2001, 59:751-7.
Christman JK: 5-azacytidine and 5-aza-2-deoxycytidine as inhibitors of
DNA methylation: mechanistic studies and their implications for cancer
therapy. Oncogene 2002, 21:5483-95.
Barbe J, Gibert I, Guerrero R: 5-azacytidine: survival and induction of the
SOS response in Escherichia coli K-12. Mutat Res 1986, 166:9-16.
Lal D, Som S, Friedman S: Survival and mutagenic effects of 5-azacytidine
in Escherichia coli. Mutat Res 1988, 193:229-36.
Donninger H, Vos MD, Clark GJ: The RASSF1A tumor suppressor. J Cell Sci
2007, 120:3163-72.
Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP: Epigenetic
inactivation of a RAS association domain family protein from the lung
tumour suppressor locus 3p21.3. Nat Genet 2000, 25:315-19.
Schildhaus HU, Krockel I, Lippert H, Malfertheiner P, Roessner A, SchneiderStock R: Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT,
DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric
junction and proximal stomach. Int J Oncol 2005, 26:1493-500.
Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Gnarra JR,
Linehan WM: Silencing of the VHL tumor-suppressor gene by DNA
methylation in renal carcinoma. Proc Natl Acad Sci USA 1994,
91:9700-9704.
Alleman WG, Tabios RL, Chandramouli GV, Aprelikova ON, Torres-Cabala C,
Mendoza A, Rogers C, Sopko NA, Linehan WM, Vasselli JR: The in vitro and
in vivo effects of reexpressing methylated von Hippel-Lindau tumor
suppressor gene in clear cell renal carcinoma with 5-aza-20deoxycytidine. Clin Cancer Res 2004, 10:7011-7021.
Li Q, Ahuja N, Burger PC, Issa JP: Methylation and silencing of the
Thrombospondin-1 promoter in human cancer. Oncogene 1999,
18:3284-3289.
Kissil JL, Feinstein E, Cohen O, Jones PA, Tsai YC, Knowles MA,
Eydmann ME, Kimchi A: DAP-kinase loss of expression in various
carcinoma and B-cell lymphoma cell lines: possible implications for role
as tumor suppressor gene. Oncogene 1997, 15:403-407.
Katzenellenbogen RA, Baylin SB, Herman JG: Hypermethylation of the
DAP-kinase CpG island is a common alteration in B-cell malignancies.
Blood 1999, 93:4347-4353.
Tang X, Sun SY, Wistuba II, Hong WK, Mao L: Hypermethylation of the
deathassociated protein kinase promoter attenuates the sensitivity to
TRAIL-induced apoptosis in human non-small cell lung cancer cells. Mol
Cancer Res 2004, 2:685-691.

Page 15 of 16

137. Reu FJ, Bae SI, Cherkassky L, Leaman DW, Lindner D, Beaulieu N,
MacLeod AR, Borden EC: Overcoming resistance to interferon-induced
apoptosis of renal carcinoma and melanoma cells by DNA
demethylation. J Clin Oncol 2006, 24:3771-3779.
138. Reu FJ, Leaman DW, Maitra RR, Bae SI, Cherkassky L, Fox MW, Rempinski DR,
Beaulieu N, MacLeod AR, Borden EC: Expression of RASSF1A, an
epigenetically silenced tumor suppressor, overcomes resistance to
apoptosis induction by interferons. Cancer Res 2006, 66:2785-2793.
139. Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J,
Gross N: Loss of caspase-8 expression in highly malignant human
neuroblastoma cells correlates with resistance to tumor necrosis factorrelated apoptosis-inducing ligand-induced apoptosis. Cancer Res 2000,
60:4315-4319.
140. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B,
Debatin KM: Sensitization for death receptor- or drug-induced apoptosis
by re-expression of caspase-8 through demethylation or gene transfer.
Oncogene 2001, 20:5865-5877.
141. Eramo A, Pallini R, Lotti F, Sette G, Patti M, Bartucci M, Ricci-Vitiani L,
Signore M, Stassi G, Larocca LM, Crino L, Peschle C, De Maria R: Inhibition
of DNA methylation sensitizes glioblastoma for tumor necrosis factorrelated apoptosis-inducing ligand mediated destruction. Cancer Res 2005,
65:11469-11477.
142. Sen R, Baltimore D: Inducibility of kappa immunoglobulin enhancerbinding protein NF-kappa B by a posttranslational mechanism. Cell 1986,
47:921-928.
143. Criswell T, Leskov K, Miyamoto S, Luo G, Boothman DA: Transcription
factors activated in mammalian cells after clinically relevant doses of
ionizing radiation. Oncogene 2003, 22:5813-5827.
144. Jung M, Dritschilo A: NF-kappa B signaling pathway as a target for
human tumor radiosensitization. Semin Radiat Oncol 2001, 11:346-351.
145. Orlowski RZ, Baldwin AS Jr: NF-kappaB as a therapeutic target in cancer.
Trends Mol Med 2002, 8:385-389.
146. Khong T, Sharkey J, Spencer A: The effect of azacitidine on interleukin-6
signaling and nuclear factor-kB activation and its in vitro and in vivo
activity against multiple myeloma. Haematologica 2008, 93:860-869.
147. Sharkey J, Khong T, Spencer A: PKC412 demonstrates JNK-dependent
activity against human multiple myeloma cells. Blood 2006, 109:1712-9.
148. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D,
Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R,
Munshi NC, Hideshima T, Anderson KC: The proteasome inhibitor PS-341
potentiates sensitivity of multiple myeloma cells to conventional
chemotherapeutic agents: therapeutic applications. Blood 2003,
101:2377-80.
149. Martin-Oliva D, Aguilar-Quesada R, O’valle F, Munoz-Gamez JA, MartinezRomero R, Garcia Del Moral R, Ruiz de Almodóvar JM, Villuendas R, Piris MA,
Oliver FJ: Inhibition of poly(ADP-ribose) polymerase modulates tumorrelated gene expression, including hypoxia-inducible factor-1 activation,
during skin carcinogenesis. Cancer Res 2006, 66:5744-5756.
150. Vo QN, Kim WJ, Cvitanovic L: The ATM gene is target for epigenetic
silencing in locally advanced breast cancer. Oncogene 2004, 23:9432-9437.
151. Kim WJ, Vo QN, Shrivastav M, Lataxes TA, Brown KD: Aberrant methylation
of the ATM promoter correlates with increased radiosensitivity in a
human colorectal tumor cell line. Oncogene 2002, 21:3864-3871.
152. Das P: Singal R DNA methylation and cancer. J Clin Oncol 2004,
22:4632-4642.
153. Dunn BK: Hypomethylation: one side of a larger picture. Ann N Y Acad Sci
2003, 983:28-42.
154. Ehrlich M: DNA methylation in cancer: too much, but also too little.
Oncogene 2002, 21:5400-5413.
155. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J: Induction of
tumors in mice by genomic hypomethylation. Science 2003, 30:0:489-492.
156. Nishigaki M, Aoyagi K, Danjoh I, Fukaya M, Yanagihara K: Discovery of
aberrant expression of R-RAS by cancer-linked DNAhypomethylation in
gastric cancer using microarrays. Cancer Res 2005, 65:2115-2124.
157. Lutz W, Leon J, Eilers M: Contributions of Myc to tumorigenesis.
Biochimica et Biophysica Acta (BBA) 2002, 1602(1):61-71.
158. Wang J, Whang H, Li Z, Wu Q: c-Myc is required for maintenance of
glioma cancer stem cells. PLoS ONE 2008, 3:e3769.
159. Jupin P, Heber AO, Littelwood T, Evan G: c-Myc-induced sensitization to
apoptosis is mediated through cytocrome c release. Genes Dev 1999,
13:1367-1381.

Gravina et al. Molecular Cancer 2010, 9:305
http://www.molecular-cancer.com/content/9/1/305

160. Bucci B, D’Agnano I, Amendola D, Citti A: Myc down-regulation sensitizes
melanoma cells to radiotherapy by inhibiting MLH1 and MSH2
mismatch repair proteins. Clin Cancer Res 2005, 11(7):2756-2767.
161. Fang JY, Yang L, Zhu HY, Chen YX, Lu J, Lu R: 5-Aza-2’-deoxycitidine
indices demethylation and up-regulates transcription of p16INK4A gene
in human gastric cancer cell lines. Chin Med J (Engl) 2009, 117(1):99-103.
162. Heller G, Schmidt WM, Ziegler B, Holzer S, Mullauer L: Genome-wide
transcriptional response to 5-Aza-2’-deoxycitdine and tricostatin A in
multiple myeloma cells. Cancer Res 2008, 68(1):44-54.
163. Eden A, Gaudet F, Waghmare A, Jaenisch R: Chromosomal instability and
tumors promoted by DNA hypomethylation. Science 2003, 300:455.
164. Yang AS, Estecio MR, Garcia-Manero G, Kantarjian HM, Issa JP: Comment on
“Chromosomal instability and tumors promoted by DNA
hypomethylation” and “Induction of tumors in mice by genomic
hypomethylation”. Science 2003, 302:1153.
165. [Http://www.vidaza.com/patient/default.aspx].
166. Dagon® (decitabine for injection). [http://www.supergen.com/].
167. Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G,
Marquez VE, Greer S, Orntoft TF, Thykjaer T, Jones PA: Preferential response
of cancer cells to zebularine. Cancer Cell 2004, 6:151-158.
168. Karpf AR, Peterson PW, Rawlins JT, Dalley BK: Inhibition of DNA
methyltransferase stimulates the expression of signal transduction and
activator transcription 1,2 and 3 genes in colon tumor cells. Proc Natl
Acad Sci 1999, 96:14007-1412.
169. Karpf AR, Lasek AW, Ririe TO, Hanks AN: Limited gene activation in tumor
and normal epithelial cells treated with the DNA methyltransferase
inhibitor 5-Aza-2’-deoxycytidine. Molecular Parmacology 2004, 65:18-27.
170. Motegi K, Azuma M, Tamatani T, Ashida Y, Sato M: Expression of
aquaporin-5 and fluid secretion from immortalized human salivary gland
cells by treatment with 5-Aza2’-deoxycytidine: a possibility for
improvement of xerostomia in patients with Sjogren syndrome. Lab
Investigation 2005, 85:342-353.
171. Benyon RC, Arthur MJ: Extracellular matrix degradation and the role of
hepatic stellate cells. Semin Liver Dis 2001, 21:373-384.
172. Hazra S, Xiong S, Wang J: Peroxisome proliferator-activated receptor
gamma induces a phenotypic switch from activated to quiescent
hepatic stellate cells. J Biol Chem 2004, 27(9):11392-11401.
173. Mann J, Oakley F, Akiboye F, Elsharkawy A, Thorne AW, Mann DA:
Regulation of myofibroblast transdifferentiation by DNA methylation
and MePC2: implication for wound healing and fribrinogenesis. Cell
Death and Differentiation 2007, 14:275-285.
174. Liberto M, Cobrinik D: Growth factor-dependent induction of p21CIP1 by
the green tea polyphenol, epigallocatechin gallate. Cancer Lett 2000,
154:151-161.
175. Sang S, Hou Z, Lambert JD, Yang CS: Redox Properties of Tea Polyphenols
and Related Biological Activities. Antioxidants & Redox Signaling 2005,
7:1704-1714.
176. Lambert JD, Sang S, Yang CS: Possible Controversy over Dietary
Polyphenols: Benefits vs Risks. Chem Res Toxicol 2007, 20:583-585.
177. Sang S, Lambert JD, Hong J, Tian S, Lee MJ, Stark RE, Ho CT, Yang CS:
Synthesis and Structure Identification of Thiol Conjugates of
(-)-Epigallocatechin Gallate and Their Urinary Levels in Mice. Chem Res
Toxicol 2005, 18:1762-176.
178. Sang S, Hou Z, Lambert JD, Yang CS: Redox Properties of Tea Polyphenols
and Related Biological Activities. Antioxidants & Redox Signaling 2005,
7:1704-1714.
179. Isbrucker RA, Edwards JA, Wolz E, Davidovich A, Bausch J: Safety studies on
epigallocatechin gallate (EGCG) preparations. Part 2: dermal, acute and
short-term toxicity studies. Food Chem Toxicol 2006, 44:636-650.
180. Yamamoto T, Hsu S, Lewis J, Wataha J: Green Tea Polyphenol Causes
Differential Oxidative Environments in Tumor versus Normal Epithelial
Cells. Journal of Pharmacology and Experimental therapeutics 2003,
307:230-237.
181. Yang CS, Lee MJ, Chen L: Human salivary tea catechin levels and
catechin esterase activities: implication in human cancer prevention
studies. Cancer Epidemiol Biomarkers Prev 1999, 8:83-89.
182. Yamamoto T, Hsu S, Lewis J, Wataha J: Green Tea Polyphenol Causes
Differential Oxidative Environments in Tumor versus Normal Epithelial
Cells. Journal of Pharmacology and Experimental therapeutics 2003,
307:230-237.

Page 16 of 16

183. Pohlmann P, DiLeone LP, Cancella AI, Caldas AP: Phase II trial of cisplatin
plus decitabine, a new DNA hypomethylating agent, in patients with
advanced squamous cell carcinoma of the cervix. Am J Clin Oncol 2002,
25:496-501.
184. Tikoo K, Yunus Ali I, Gupta J, Gupta C: 5-Azaytidine prevents Cisplatin
induced nephrotoxicity and potentiates anticancer activity of Cisplatin
by involving inhibition of metallothionenin, pAKT and DNMT1
expression in chemical induced cancer rats. Toxicology Letters 2009,
191:158-166.
185. Qui H, Hashimiro M, Shinto O, Matsuzaki T, Hirakawa K: DNA
methyltransferase inhibitor 5-Aza-CdR enhances the radiosensitivity of
gastric cancer cells. Cancer Sci 2009, 100:181-188.
186. Santi DV, Garret CE, Barr Pj: On the mechanism of inhibition of DNA
cytosine methyltransferase by cytosine anlogs. Cell 1983, 33:9-10.
187. Christman JK: 5-azacytidine and 5-Aza-2’deoxycytidine as inhibitors of
DNA methylation: mechanistic studies and their implications for cancer
therapy. Oncogene 2002, 21:5483-5495.
188. Karpf AR, Moore BC, Ririe TO, Jones DA: Activation of the p53 DNA
damage response pathway after inhibition of DNA methyltransferase by
5-Aza-2’-deoxycytidine. Mol Pharmacol 2001, 59:751-757.
189. Neylon C, Kralicek AV, Hill TM, Dixon NE: Replication termination in
Escherichia coli: structure and antihelicase activity of the Tus-Ter
complex. Microbiol Mol Biol Rev 2005, 69:501-526.
190. Siaglotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HY, Anzalone L,
Pezzani L, Di Giacomo AM, Fonsatti E, Coalizzi F, Altomonte M, Calbrò L,
Maio M: Epigenetic Drugs as Pleiotropic Agents in Cancer Treatment:
Biomolecular Aspects and Clinical Applications. J Cell Physiol 2007,
212:330-344.
191. Mund C, Brueckner B, Lyko F: Reactivation of Epigenetically Silenced
Genes by DNA Methyltransferase Inhibitors: Basic Concepts and Clinical
Applications. Epigenetics 2006, 1:1, 7-13.
192. Griffiths EA, Gore SV: DNA Methyltransferase and Histone Deacetylase
Inhibitors in the Treatment of Myelodysplastic Syndromes. Semin
Hematol 2008, 45(1):23-30.
doi:10.1186/1476-4598-9-305
Cite this article as: Gravina et al.: Biological rationale for the use of DNA
methyltransferase inhibitors as new strategy for modulation of tumor
response to chemotherapy and radiation. Molecular Cancer 2010 9:305.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit

